|
Efficacy and safety of nivolumab in renal cell carcinoma patients with BONE metastases: Results of the GETUG: AFU 26 nivoren multicenter phase II study. |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Bristol-Myers Squibb; Ipsen; Novartis; Pfizer |
Travel, Accommodations, Expenses - AstraZeneca; Bristol-Myers Squibb; MSD Oncology; Pfizer/Ipsen |
|
|
Consulting or Advisory Role - AstraZeneca (Inst); Bayer (Inst); BMS (Inst); IPSEN (Inst); Janssen (Inst); MSD Oncology (Inst); Pfizer (Inst); Sanofi/Aventis (Inst) |
Speakers' Bureau - Amgen (Inst); Astellas Pharma (Inst); BMS (Inst); Ipsen (Inst); Janssen Oncology (Inst); MSD Oncology (Inst); Sanofi/Aventis (Inst) |
Research Funding - BMS (Inst) |
Travel, Accommodations, Expenses - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Ipsen; Janssen Oncology; Pfizer; Sanofi |
|
|
Honoraria - Bristol-Myers Squibb; Ipsen; MSD Oncology; Novartis; Pfizer |
Consulting or Advisory Role - Bristol-Myers Squibb; Ipsen; MSD Oncology; Novartis; Pfizer |
Research Funding - IPSEN (Inst); Pfizer (Inst) |
Travel, Accommodations, Expenses - Bristol-Myers Squibb; IPSEN; Novartis; Pfizer |
|
|
Honoraria - Astellas Pharma; AstraZeneca; Ipsen; Ipsen; Ipsen; Janssen-Cilag; MSD Oncology |
Travel, Accommodations, Expenses - Astellas Pharma; Janssen; Janssen Oncology; Novartis; Pfizer; Pfizer; pfizer |
|
|
Consulting or Advisory Role - Amgen; amgen; Astellas Medivation; AstraZeneca; Bayer/Onyx; Bristol-Myers Squibb; ipsen; Janssen-Cilag; MSD Oncology; Pfizer; Roche; Sanofi |
Research Funding - AstraZeneca (Inst); AstraZeneca (Inst); BMS (Inst); ipsen (Inst); Janssen-Cilag (Inst); Merck (Inst); MSD Oncology (Inst); Pfizer (Inst); Roche (Inst) |
Travel, Accommodations, Expenses - Astellas Pharma; AstraZeneca; AstraZeneca; ipsen; ipsen; ipsen; Janssen-Cilag; pfizer; Roche |
Other Relationship - Janssen |
|
|
Research Funding - Novartis (Inst) |
Expert Testimony - Astellas Pharma; Bristol-Myers Squibb; Ipsen; Janssen Oncology; Lilly; Novartis; Pfizer; Roche; Sanofi |
Travel, Accommodations, Expenses - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Ipsen; Janssen Oncology; Novartis; Pfizer; Sanofi |
|
|
No Relationships to Disclose |
|
|
Honoraria - BMS; Ipsen; Merck serono; Pfizer |
Consulting or Advisory Role - Ipsen |
Travel, Accommodations, Expenses - Ipsen; Janssen Oncology; Merck KGaA; MSD Oncology |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - AstraZeneca |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Honoraria - Astellas Pharma; BMS; IPSEN; Janssen-Cilag; Merck KGaA; MSD; Novartis; Pfizer |
Consulting or Advisory Role - Amgen; AstraZeneca; BMS; Eisai; ipsen; Janssen-Cilag; Merck KGaA; MSD Oncology; Pfizer |
Travel, Accommodations, Expenses - Astellas Pharma; BMS; IPSEN; Janssen-Cilag; MSD; Pfizer |
|
|
No Relationships to Disclose |
|
|
Honoraria - Bristol-Myers Squibb; Ipsen; Oncorena; Pfizer |
Consulting or Advisory Role - AVEO; Bristol-Myers Squibb; Ipsen; Oncorena; Pfizer |
Research Funding - BMS France (Inst) |
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Ipsen; MSD |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Corvus Pharmaceuticals (Inst); Exelixis (Inst); Ipsen (Inst); Janssen (Inst); Merck (Inst); MSD (Inst); Novartis (Inst); Peloton therapeutics (Inst); Pfizer (Inst); Roche (Inst) |
Research Funding - Bristol-Myers Squibb (Inst) |
Travel, Accommodations, Expenses - Bristol-Myers Squibb; MSD |
|
|
No Relationships to Disclose |